Cargando…
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
BACKGROUND: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane. METHODS: Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hos...
Autores principales: | Gagnon, Nadia, Bernard, Sophie, Paquette, Martine, Alguire, Catherine, Lacroix, André, Hétu, Pierre-Olivier, Olney, Harold J, Bourdeau, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259324/ https://www.ncbi.nlm.nih.gov/pubmed/37435450 http://dx.doi.org/10.1530/EO-21-0021 |
Ejemplares similares
-
THU609 Timeline For Undetectable Mitotane Plasma Levels In Adrenocortical Carcinoma Patients After Stopping Treatment
por: Younes, Nada, et al.
Publicado: (2023) -
SAT-158 New Data on High Prevalence and Time of Occurrence of New Onset Hypothyroidism Associated with Mitotane Therapy in a Cohort of Adrenocortical Cancer
por: Poirier, Jonathan, et al.
Publicado: (2020) -
SAT-169 Adrenocortical Cancer Is Diagnosed at Large Size and Advanced Stage in a Canadian Referral Center; Focus on Modes of Presentation Depending on Stages
por: Poirier, Jonathan, et al.
Publicado: (2020) -
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020) -
Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature
por: Ghorayeb, Nada El, et al.
Publicado: (2016)